Three-Year and Five-Year Outcomes of a Phase II Study of Perioperative CapeOxTherapy for Advanced Gastric Cancer with Extensive Lymph Node Metastasis (OGSG1701)
2025
A Multicenter Phase II Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Final outcomes of the phase II OGSG1902 trial
Conversion Surgery for Stage IV Gastric Cancer: Real-World Insights with a Focus on Elderly Patients (OGSG2301)
Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial
Conversion Surgery in Advanced Gastric Cancer Patients Aged over 80 : Results from a Multi-Institutional Retrospective Study (OGSG2301)
進行胃癌に対する周術期capecitabine＋oxaliplatin(CapeOx)療法の術前化学療法としての有用性（OGSG1601、1701試験より）
ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer
Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for patients with gastrointestinal cancer and iron deficiency anemia undergoing chemotherapy